Novartis’ Gleevec Patent Challenged in the US?
With characteristic flair, CH Unnikrishnan of Livemint is again the first to unearth this interesting story: “US drugs regulator food and drug administration (FDA) has accepted a generic challenge by India’s Sun Pharmaceuticals Industries Ltd against Glivec, a controversial mega-earner cancer drug of Novartis AG, potentially weakening the Swiss drug maker’s petition against an Indian ruling denying the drug a patent. The challenge in the US, if it invalidates Novartis’ patent, will not only significantly stre-ngthen the plea of local […]
Novartis’ Gleevec Patent Challenged in the US? Read More »

